dc.contributor | IDIAP Jordi Gol |
dc.contributor.author | Castellsagué, Jordi |
dc.contributor.author | Linder, Marie |
dc.contributor.author | Scholle, Oliver |
dc.contributor.author | Calingaert, Brian |
dc.contributor.author | Bui, Christine |
dc.contributor.author | Arana, Alejandro |
dc.contributor.author | Laguna, Clara |
dc.contributor.author | Gonzalez-Rubio, Francisca |
dc.contributor.author | Giner-Soriano, Maria |
dc.contributor.author | Roso-Llorach, Albert |
dc.contributor.author | Poblador-Plou, Beatriz |
dc.contributor.author | Prados-Torres, Alexandra |
dc.contributor.author | Perez-Gutthann, Susana |
dc.date.accessioned | 2019-02-21T10:01:44Z |
dc.date.available | 2019-02-21T10:01:44Z |
dc.date.issued | 2018-09-27 |
dc.identifier.citation | Castellsague J, Poblador‐Plou B, Giner‐Soriano M, Linder M, Scholle O, Calingaert B, et al. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf. 2018;27(9):953-961. |
dc.identifier.issn | 1099-1557 |
dc.identifier.uri | https://hdl.handle.net/11351/3804 |
dc.description | Claudicació intermitent; Malaltia vascular perifèrica; Minimització del risc |
dc.description.sponsorship | Otsuka Pharmaceutical Europe Ltd. |
dc.language.iso | eng |
dc.publisher | John Wiley and Sons |
dc.relation.ispartofseries | Pharmacoepidemiology and Drug Safety;27(9) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Claudicació intermitent - Tractament |
dc.subject | Medicaments - Eficàcia |
dc.subject | Claudicació intermitent - Estudi de casos |
dc.subject.mesh | Intermittent Claudication |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Comparative Study |
dc.title | Effectiveness of risk minimization measures for the use ofcilostazol in United Kingdom, Spain, Sweden, and Germany |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/pds.4584 |
dc.subject.decs | claudicación intermitente |
dc.subject.decs | /tratamiento farmacológico |
dc.subject.decs | estudio comparativo |
dc.relation.publishversion | https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4584 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.aplicacio.versio | Adobe acrobat reader DC 2018.011.20058 |
dc.aplicacio.aplicacio | pdf |
dc.imatge.resolucio | 300 ppp |
dc.imatge.profunditatBits | 8 bit |
dc.contributor.authoraffiliation | [Castellsague J, Arana A, Perez-Gutthan S] Epidemiology, RTI Health Solutions, Barcelona, Spain. [Poblador-Plou B, Laguna C, Gonzalez-Rubio F, Prados-Torres A] Aragon Health Sciences Institute (IACS), IISAragon, Hospital Universitario Miguel Servet,University of Zaragoza, Zaragoza, Spain. [Giner-Soriano M, Roso-Llorach A] Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain. [Linder M] Centre for Pharmacoepidemiology, Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. [Scholle O] Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany. [Calingaert B, Bui C] Epidemiology, RTI Health Solutions, Research Triangle Park, NC, USA |
dc.identifier.pmid | 30043552 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |